Sangamo Therapeutics (SGMO) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to -$34.9 million.
- Sangamo Therapeutics' Income towards Parent Company fell 42730.51% to -$34.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$108.9 million, marking a year-over-year increase of 1923.09%. This contributed to the annual value of -$97.9 million for FY2024, which is 6201.35% up from last year.
- Latest data reveals that Sangamo Therapeutics reported Income towards Parent Company of -$34.9 million as of Q3 2025, which was down 42730.51% from -$20.0 million recorded in Q2 2025.
- In the past 5 years, Sangamo Therapeutics' Income towards Parent Company ranged from a high of $21.1 million in Q1 2023 and a low of -$114.5 million during Q2 2023
- Moreover, its 5-year median value for Income towards Parent Company was -$44.0 million (2022), whereas its average is -$42.7 million.
- As far as peak fluctuations go, Sangamo Therapeutics' Income towards Parent Company tumbled by 306326.26% in 2021, and later skyrocketed by 14800.88% in 2023.
- Quarter analysis of 5 years shows Sangamo Therapeutics' Income towards Parent Company stood at -$37.5 million in 2021, then plummeted by 38.63% to -$51.9 million in 2022, then fell by 16.08% to -$60.3 million in 2023, then skyrocketed by 61.2% to -$23.4 million in 2024, then plummeted by 49.3% to -$34.9 million in 2025.
- Its Income towards Parent Company was -$34.9 million in Q3 2025, compared to -$20.0 million in Q2 2025 and -$30.6 million in Q1 2025.